Abstract
Recent decades have seen the introduction of many new therapeutics into pediatric rheumatology practice, particularly biologic disease-modifying antirheumatic drugs (bDMARD). These advances are a result of the biotechnological revolution in the pharmaceutical industry, specific legislation for the development of pediatric medicines, and large international collaborative networks.